AROAF
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more
AROAF (AROAF) - Total Liabilities
Latest total liabilities as of March 2025: $14.35 Million USD
Based on the latest financial reports, AROAF (AROAF) has total liabilities worth $14.35 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AROAF - Total Liabilities Trend (2021–2025)
This chart illustrates how AROAF's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AROAF Competitors by Total Liabilities
The table below lists competitors of AROAF ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Broadband Technology Co Ltd
SHG:600608
|
China | CN¥78.63 Million |
|
DIAMOND BIOFUND INC
TW:6901
|
Taiwan | NT$168.32 Million |
|
Taiyen Biotech Co Ltd
TW:1737
|
Taiwan | NT$1.45 Billion |
|
Siamgas and Petrochemicals Public Company Limited
BK:SGP
|
Thailand | ฿37.32 Billion |
|
Namsun Alumini
KO:008350
|
Korea | ₩144.33 Billion |
|
Apollo Pipes Limited
NSE:APOLLOPIPE
|
India | ₹2.91 Billion |
|
Talga Group Ltd
PINK:TLGRF
|
USA | $6.61 Million |
|
Vaxcell-Bio Therapeutics Co. Ltd
KQ:323990
|
Korea | ₩5.28 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down AROAF's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AROAF's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AROAF (2021–2025)
The table below shows the annual total liabilities of AROAF from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $14.35 Million | -2.98% |
| 2024-03-31 | $14.79 Million | +7.97% |
| 2023-03-31 | $13.69 Million | +21.15% |
| 2022-03-31 | $11.30 Million | -41.83% |
| 2021-03-31 | $19.43 Million | -- |